In8bio Inc (INAB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.86M
Last updated: Nov 17, 2026 at 11:04 AM ET
In8bio Inc (INAB) Stock Forecast
Analysts expect In8bio (INAB) to earn -$1.11 per share in the fiscal year ending Dec 31, 2026. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 33.3% |
| Buy | 2 | 66.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$1.11
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.95
- EPS consensus, revenue $1.11M
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.11 | -$1.49 to -$0.89 | 3 | N/A | N/A | 3 |
| Dec 31, 2027 | -$0.95 | -$1.24 to -$0.64 | 3 | $1.11M | N/A | 3 |
Quarterly Estimates
The EPS consensus rises from -$0.36 for the quarter ending Dec 31, 2026 to -$0.33 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.36 | -$0.64 to -$0.18 | 5 |
| Mar 31, 2027 | -$0.33 | -$0.33 to -$0.33 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 2 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.24.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.11 | -$1.09 | -$1.09 | -$1.24 | -$1.24 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.95 | -$0.97 | -$0.97 | -$1.06 | -$1.06 | N/A |
| Quarter ending Mar 31, 2027 | -$0.33 | -$0.39 | -$0.39 | -$0.39 | N/A | N/A |
Frequently Asked Questions About INAB
What is the INAB stock forecast?
Consensus analyst estimates put In8bio's EPS at -$1.11 for the fiscal year ending Dec 31, 2026. The consensus rating from 3 analysts is Buy.
How do analysts rate INAB stock?
Of 3 analysts covering In8bio, 1 rates it Strong Buy, 2 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from INAB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.11, with estimates from -$1.49 to -$0.89 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.95, with estimates from -$1.24 to -$0.64 from 3 analysts.
What revenue do analysts expect from In8bio next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.11M.
How many analysts cover INAB?
3 analysts rate In8bio stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
INAB pages: Overview, Earnings, Forecast, Financials, Competitors